Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh

BACKGROUND: Hyperinflammation-induced respiratory failure is a leading cause of mortality in COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are the drug-of-choice to suppress cytokine storm in COVID-19. Here, we compared the therapeutic safety and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasan, Md Jahidul, Rabbani, Raihan, Anam, Ahmad Mursel, Huq, Shihan Mahmud Redwanul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903771/
https://www.ncbi.nlm.nih.gov/pubmed/35238257
http://dx.doi.org/10.1080/07853890.2022.2039958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903771/
https://www.ncbi.nlm.nih.gov/pubmed/35238257
http://dx.doi.org/10.1080/07853890.2022.2039958

Ejemplares similares